Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses the use of a robotic system for hair graft harvesting in hair restoration surgery, focusing on its capabilities and the advantages and disadvantages, but it reports no new clinical findings.

This review classifies engineered nanomaterials by composition and application in biomedicine, highlighting diverse uses like regenerative medicine and potential occupational side effects, but reports no new clinical results.

This review identifies FDA-cleared home-use photobiomodulation devices for androgenetic alopecia treatment and highlights their excellent safety profile but notes the lack of long-term comparative studies.

This review explores stem cell applications for hair regrowth in alopecia, with no new clinical results, suggesting potential advantages over current FDA-approved treatments.

This review highlights current and future AI applications in hair restoration and diagnosis of hair disorders, including automated systems for hair detection and self-diagnosis, emphasizing the need for experts to understand their benefits and limitations.

Follicular unit transplantation treats hair loss and restores eyebrows with short recovery and natural results.

This study prepared and evaluated a polyherbal hair oil using plant-based ingredients, finding that it met standard parameters and effectively addressed hair problems such as growth and dandruff, with FDA approval for clinical use.

This review discusses the application of low-level light therapy for hair loss treatment, particularly androgenetic alopecia, and reports no new clinical results; the authors suggest consideration of light source characteristics and potential pros and cons.

In this study, Aminoacridine, Abemaciclib, and the combination of Aminoacridine with Minoxidil showed potential for effective hair regeneration by activating Wnt/β-catenin signaling in animal experiments.

This review discusses the increasing prevalence of alopecia in younger populations and outlines the need for better understanding its pathogenesis to develop effective treatments. It also examines current FDA-approved drugs and emerging small molecule compounds with potential anti-alopecia effects.

In this literature review, exosomes show promise in cosmetic dermatology for skin rejuvenation and hair restoration; however, challenges like inconsistent isolation methods and lack of FDA approval necessitate further clinical trials to ensure long-term safety and efficacy.

This review highlights advancements in the understanding and treatment of alopecia areata, noting that the approval of oral Janus kinase inhibitors like baricitinib and ritlecitinib marks a significant development in managing severe cases of this autoimmune condition.

Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.

This review indicates that many former FDA category D and X systemic dermatologic medications may negatively impact male fertility, with further research needed to assess potential teratogenic effects.

This narrative review concludes that long-term randomized controlled trials are needed to establish clear guidelines for testosterone therapy in women, given the lack of FDA-approved formulations and the variable quality of current treatments.

This article discusses the development and testing of comprehensible over-the-counter drug product labels, highlighting the need for improved consumer understanding and calling for further research on label design.

Scalp hypothermia can prevent chemotherapy-induced hair loss but is not suitable for all patients, and more research is needed to improve prevention methods.

This study found that finasteride was associated with more reproductive adverse effects, including sexual dysfunction in men and fetal harm in women, compared to minoxidil in reported alopecia cases.

This review discusses low-level light therapy for androgenetic alopecia and female pattern hair loss, noting minimal clinical evidence on its efficacy and the need for more controlled studies.

This review discusses the factors affecting laser hair removal results and adverse events, emphasizing the need for more research to determine optimal treatment parameters; it reports no new clinical findings.

This review summarizes existing literature on the safety of commonly used dermatologic medications during pregnancy but does not present new clinical findings, aiming to assist physicians with prescribing decisions.

This review discusses the JAK-STAT pathway and the use of FDA-approved JAK inhibitors for autoimmune and inflammatory diseases but reports no new research findings.

This retrospective pharmacovigilance study reviewed adverse event reports from 2004 to 2025 for drugs treating benign prostatic hyperplasia, identifying distinct safety signals for α1-blockers, 5ARIs, and PDE5I, including some potential new adverse events that require further investigation.

This review summarizes current and emerging treatments for common hair loss conditions, highlighting good evidence for androgenetic alopecia but noting the lack of long-term data for alopecia areata and cicatricial alopecias.

This review examines the incidence and management of dermatologic adverse effects from FDA-approved oral targeted cancer therapies, highlighting frequent occurrences like rashes and rarer severe conditions such as Stevens-Johnson Syndrome.

This review found that hormonal therapies, including FDA-approved combined oral contraceptive pills and spironolactone, are effective and well-tolerated treatments for acne vulgaris in adolescents with or without endocrine disorders, providing alternative options to antibiotics.

This review discusses current and emerging treatments for alopecia areata, emphasizing systemic treatments for moderate to severe cases, and reports no new clinical results.

This review highlights the variability and unpredictability of alopecia areata, ranging from single scalp patches to total body hair loss, and notes the 2022 approval of the first AA-specific drug, baricitinib, potentially spurring new research into targeted treatments.

This article discusses alopecia areata, highlighting its autoimmune nature and the lack of FDA-approved treatments, without providing new research findings.

This review discusses the characteristics and management of adolescent androgenetic alopecia, noting a lack of FDA-approved treatments and reporting no new clinical results.